Zydus Cadila gets USFDA nod for hypertension drug

Zydus Cadila said it received the final approval from the USFDA to sell Spironolactone Tablets, used to treat blood pressure and heart failure.

The tablets, in strengths of 25 mg, 50 mg and 100 mg, will be used for lowering high blood pressure to prevent strokes, heart attacks and kidney problems.

It is also used to treat swelling (edema) caused by certain conditions like heart failure and liver disease by removing excess fluid and improving symptoms such as breathing problems.

The company did not specify the market size of the medicine.

The drug will be manufactured at the group’s manufacturing facility at Baddi.

With this, said Cadila, the group now has 210 approvals in the US out of the 330 applications filed since 2003-04.

Cadila was founded in 1952 by Ramanbhai Patel, formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi.

It evolved over the next four decades into an established pharmaceutical company and is today one of the world’s largest producers of generic drugs.